新辅助化疗方案治疗三阴乳腺癌的疗效观察

目的探讨新辅助化疗方案治疗三阴乳腺癌的疗效。方法选取2009年1月～2013年1月在我院接受治疗的三阴乳腺癌患者88例作为研究对象,随机分为对照组与观察组,对照组采用AC（阿霉素＋环磷酰胺）新辅助化疗方案,观察组采用ET（蒽环类＋多西紫杉醇）新辅助化疗方案,对比两组患者的疗效、肿瘤标志物CA15-3转阴的疗程数以及并发症情况。结果 AC与ET组的新辅助化疗有效率分别为54.8%及80.5%,对比具有统计学意义（χ2=9.386,P=0.025）,肿瘤标志物CA15-3转阴的疗程对比χ2=5.427,P=0.019,具有统计学意义;不良反应较轻,经对症处理均能完成化疗疗程。结论新辅助化疗方案对三阴乳腺癌疗效肯定,但仍有一定的局限性,其中以蒽环类联合紫杉醇类效果较好。

Clinical Observation of Neoadjuvant Chemotherapy in the Treatment of Triple-negative Breast Cancer

Objective To explore the efficacy of the neoadjuvant chemotherapy in the treatment of triple- negative breast cancer. Methods 88 patients with triplenegative breast cancer were chosen as research subjects from January 2009 to January 2013 in our hospital. The patients were randomly divided into control group and observation group, the control group were used AC（doxorubicin＋eyelophosphamide） as treatment options, the observation group were used ET（anthracycline＋docetaxel） as treatment options. The efficacy of patients in two groups, the number courses of tumor maker Ca15-3 negative, and com- plication were observed. Results The response rates of AC and ET group were 54.8% and 80.5%. There were significant differences between two groups,χ2=9.386,P=0.025. The negative numbercourses of tumor marker CA15-3 compared χ2=5.427, P=0.019, with statistical significance. All the patients completed the chemotherapy treatment after Symptomatic treatment. Conclusion The neoadjuvant chemotherapy for TNBC was effective, but there were still some limitations, anthracy- clines and paclitaxel class group, had better efficacy.